FDA Fast-Tracks New Blood Cancer Treatment CLN-049 for AML

Cullinan Therapeutics (CGEM) receives FDA Fast Track designation for CLN-049, a novel therapy showing promising results in treating relapsed acute myeloid leukemia patients.